Robust financing to support advancement of Immusoft’s novel B cell platform
Immusoft Receives Rare Pediatric Disease Designation for Treatment of MPS I
Acquisition Adds Fast-Acting Neurotoxin Programs with 2 to 4-Week Duration to Allergan's Best-in-Class Medical Aesthetics Portfolio and Pipeline
Federal grant will be used to help company advance B cell technology
Dr. Jean Carruthers to Highlight Key Aesthetic Clinical Study Results for This Novel Neurotoxin with a Unique Clinical Profile.